I-Mab (IMAB)
NASDAQ: IMAB · Real-Time Price · USD
0.923
-0.030 (-3.17%)
At close: Dec 20, 2024, 4:00 PM
0.953
+0.030 (3.27%)
After-hours: Dec 20, 2024, 6:26 PM EST
I-Mab Employees
I-Mab had 220 employees as of December 31, 2023. The number of employees decreased by 158 or -41.80% compared to the previous year.
Employees
220
Change
-158
Growth
-41.80%
Revenue / Employee
$15,064
Profits / Employee
-$374,051
Market Cap
75.23M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 220 | -158 | -41.80% |
| Dec 31, 2021 | 378 | 150 | 65.79% |
| Dec 31, 2020 | 228 | 43 | 23.24% |
| Dec 31, 2019 | 185 | 51 | 38.06% |
| Dec 31, 2018 | 134 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| 23andMe Holding Co. | 582 |
| Adlai Nortye | 127 |
| Theratechnologies | 103 |
| ALX Oncology Holdings | 72 |
| InspireMD | 66 |
| PMV Pharmaceuticals | 63 |
| Ikena Oncology | 43 |
| Quince Therapeutics | 32 |
IMAB News
- 4 weeks ago - I-Mab to Participate at the Piper Sandler Healthcare Conference - PRNewsWire
- 5 weeks ago - I-Mab Reports Third Quarter 2024 Results - PRNewsWire
- 6 weeks ago - I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer - PRNewsWire
- 7 weeks ago - I-Mab to Release Q3 2024 Financial Results on November 14, 2024 - PRNewsWire
- 7 weeks ago - I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024 - PRNewsWire
- 7 weeks ago - I-Mab to Participate at the Truist Securities BioPharma Symposium - PRNewsWire
- 3 months ago - I-Mab Presents Updated Phase 1 Givastomig Data at ESMO 2024 - PRNewsWire
- 3 months ago - I-Mab Presents Positive Uliledlimab Pharmacokinetics Data at 2024 World Conference on Lung Cancer - PRNewsWire